Complement Inhibition in Geographic Atrophy: Time to Prepare for Novel Treatments (CME Monograph)
Activity Description and Purpose
This educational activity is designed for clinicians to gain a clear understanding of the pathophysiology of geographic atrophy (GA) as it relates to disease management, including identifying key characteristics of GA on imaging. Clinical data for the complement inhibitors pegcetacoplan and avacincaptad pegol are outlined in a manner that will help clinicians develop appropriate treatment plans for patients with GA. The desired results of this educational activity are for clinicians to enhance their knowledge of the prevalence and pathophysiology of GA and new and emerging treatment options for GA and to improve their competence in identifying and managing patients with GA.
This educational activity is intended for retina specialists and other ophthalmologists.
After completing this activity, participants will be better able to:
- Describe the pathophysiology of geographic atrophy as it relates to disease management
- Identify the features of geographic atrophy on imaging
- Review clinical trial data for therapy that targets complement for geographic atrophy
- Develop appropriate treatment plans for patients with geographic atrophy
Carl D. Regillo, MD (Chair)
|Roger A. Goldberg, MD, MBA|
Bay Area Retina Associates
Walnut Creek, California
California Pacific Medical Center Ophthalmology Residency
San Francisco, California
|Christina Y. Weng, MD, MBA|
Professor of Ophthalmology
Fellowship Program Director, Vitreoretinal Diseases & Surgery
Baylor College of Medicine
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Roger A. Goldberg, MD, MBA, is a consultant for AbbVie Inc, Annexon Inc, Apellis Pharmaceuticals, EyePoint Pharmaceuticals, and Regeneron Pharmaceuticals, Inc; is an advisory board member of Boehringer Ingelheim International GmbH, Genentech, Inc, and Outlook Therapeutics, Inc; is on the speakers bureau for Apellis Pharmaceuticals, Biogen Idec, and Genentech, Inc; is a contracted researcher for AffaMed Therapeutics, Annexon Inc, Apellis Pharmaceuticals, Boehringer Ingelheim International GmbH, EyePoint Pharmaceuticals, Genentech, Inc, Janssen Pharmaceuticals, Inc, and Neurotech Pharmaceuticals.
Carl D. Regillo, MD, is a consultant for Adverum, Allergan, Annexon Inc, Apellis Pharmaceuticals, Aviceda Therapeutics, Clearside Biomedical, Inc, EyePoint Pharmaceuticals, 4DMT, Genentech, Inc, Iveric Bio, Inc, Janssen Pharmaceuticals, Inc, NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Ocugen, Inc, Regenxbio Inc, Stealth BioTherapeutics Inc, Thea Pharmaceuticals Limited, and Zeiss.
Christina Y. Weng, MD, MBA, is a consultant for AbbVie Inc, Alcon, Alimera Sciences, Allergan, D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., Genentech, Inc, Iveric Bio, Inc, Novartis Pharmaceuticals Corporation*, Regeneron Pharmaceuticals, Inc, and Regenxbio Inc; and is a contracted researcher for AGTC and Alimera Sciences.
Hadi Kaakour, MD, MS, is an advisory board member of Alimera Sciences*.
Planners, Managers, and Writers
Medical Writer: Tony Realini, MD, is a consultant for iSTAR Medical*, Ivantis Inc*, New World Medical, Inc, Ocular Therapeutix, Inc, Oyster Point Pharma Inc, and Sight Sciences.
Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS*.
Other MedEdicus planners and managers have no relevant commercial relationships to disclose.
* The financial relationship existed during the past 24 months but has now ended
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Iveric Bio, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Iveric Bio, Inc, or Retina Specialist.
©2023 MedEdicus LLC. 296.1b
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation